The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM).
Axel Hauschild
Consultant or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Roche
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Roche
Research Funding - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Roche
Jean Jacques Grob
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Merck; Roche
Honoraria - GlaxoSmithKline; Merck; Roche
Lev V. Demidov
No relevant relationships to disclose
Thomas Jouary
No relevant relationships to disclose
Ralf Gutzmer
Consultant or Advisory Role - Almirall Hermal GmbH; Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche
Honoraria - Almirall Hermal GmbH; Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Merck Serono; MSD; Novartis; Roche
Research Funding - Novartis; Roche
Other Remuneration - Bristol-Myers Squibb; GlaxoSmithKline; Roche
Michael Millward
Consultant or Advisory Role - GlaxoSmithKline
Piotr Rutkowski
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Roche
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer
Christian U. Blank
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Roche
Honoraria - GlaxoSmithKline; Novartis
Research Funding - Bristol-Myers Squibb
Wilson H. Miller
No relevant relationships to disclose
Eckhart Kaempgen
No relevant relationships to disclose
Salvador Martin-Algarra
Consultant or Advisory Role - GlaxoSmithKline
Boguslawa Karaszewska
No relevant relationships to disclose
Cornelia Mauch
No relevant relationships to disclose
Vanna Chiarion-Sileni
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Roche
Beloo Mirakhur
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Mary E. Guckert
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
R. Suzanne Swann
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Patricia Haney
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Vicki L. Goodman
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Paul B. Chapman
Consultant or Advisory Role - GlaxoSmithKline
Research Funding - Genentech; GlaxoSmithKline